Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$32.13
+1.4%
$39.94
$31.10
$63.46
$3.84B0.811.66 million shs2.26 million shs
Harrow, Inc. stock logo
HROW
Harrow
$26.66
+9.3%
$24.80
$11.39
$59.23
$978.02M0.41508,740 shs699,757 shs
Perrigo Company plc stock logo
PRGO
Perrigo
$26.99
-0.1%
$26.38
$23.14
$31.17
$3.68B0.451.53 million shs2.55 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$58.97
+2.8%
$56.95
$35.17
$68.58
$3.65B2.36546,010 shs561,969 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
+1.39%-12.38%-16.87%-22.69%-48.26%
Harrow, Inc. stock logo
HROW
Harrow
+9.26%+7.80%+10.67%-16.03%+129.83%
Perrigo Company plc stock logo
PRGO
Perrigo
-0.04%+7.06%+9.75%+11.55%-12.11%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
+2.79%-8.45%-0.97%+2.41%+50.66%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
4.1394 of 5 stars
4.42.00.04.62.40.80.0
Harrow, Inc. stock logo
HROW
Harrow
2.0506 of 5 stars
3.51.00.00.02.02.50.6
Perrigo Company plc stock logo
PRGO
Perrigo
4.6981 of 5 stars
2.13.04.23.52.82.52.5
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
4.1031 of 5 stars
4.51.00.04.32.10.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.89
Moderate Buy$74.44131.68% Upside
Harrow, Inc. stock logo
HROW
Harrow
3.00
Buy$61.25129.74% Upside
Perrigo Company plc stock logo
PRGO
Perrigo
2.25
Hold$33.0022.27% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
3.00
Buy$75.3827.84% Upside

Current Analyst Ratings Breakdown

Latest HROW, CYTK, RYTM, and PRGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
Harrow, Inc. stock logo
HROW
Harrow
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$57.00 ➝ $60.00
5/8/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$55.00 ➝ $53.00
5/7/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$82.00 ➝ $80.00
5/7/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$86.00 ➝ $80.00
5/7/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$66.00 ➝ $72.00
5/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$47.00 ➝ $41.00
5/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
4/24/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Overweight$55.00
4/21/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$120.00 ➝ $120.00
4/15/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$62.00 ➝ $54.00
4/15/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$120.00 ➝ $120.00
(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$19.22M199.67N/AN/A($3.94) per share-8.15
Harrow, Inc. stock logo
HROW
Harrow
$199.61M4.90N/AN/A$2.01 per share13.26
Perrigo Company plc stock logo
PRGO
Perrigo
$4.34B0.85$5.63 per share4.79$35.19 per share0.77
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$136.86M27.41N/AN/A$2.87 per share20.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$526.24M-$5.29N/AN/AN/A-17,906.25%N/A-50.21%N/A
Harrow, Inc. stock logo
HROW
Harrow
-$24.41M-$0.44N/A66.65N/A-19.75%-45.57%-8.87%N/A
Perrigo Company plc stock logo
PRGO
Perrigo
-$12.70M-$1.31N/A8.82N/A-3.64%7.38%3.18%8/1/2025 (Estimated)
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$184.68M-$2.81N/AN/AN/A-230.07%-367.36%-77.47%N/A

Latest HROW, CYTK, RYTM, and PRGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Harrow, Inc. stock logo
HROW
Harrow
$0.02-$0.38-$0.40-$0.50$57.00 million$47.83 million
5/7/2025Q1 2025
Perrigo Company plc stock logo
PRGO
Perrigo
$0.56$0.60+$0.04-$0.05$1.09 billion$1.04 billion
5/7/2025Q1 2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 million
5/6/2025Q1 2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million
3/27/2025Q4 2024
Harrow, Inc. stock logo
HROW
Harrow
$0.11$0.25+$0.14$0.24$66.01 million$66.83 million
2/27/2025Q4 2024
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.29-$1.26+$0.03-$1.26$14.26 million$16.93 million
2/27/2025Q4 2024
Perrigo Company plc stock logo
PRGO
Perrigo
$0.92$0.93+$0.01-$0.32$1.20 billion$1.14 billion
2/26/2025Q4 2024
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.69-$0.72-$0.03-$0.72$38.48 million$41.83 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
N/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
$1.164.30%+4.77%N/A 23 Years
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A

Latest HROW, CYTK, RYTM, and PRGO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/30/2025
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.294.55%5/30/20255/30/20256/17/2025
2/19/2025
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.294.68%3/7/20253/7/20253/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
5.93
9.28
9.28
Harrow, Inc. stock logo
HROW
Harrow
3.23
1.55
1.44
Perrigo Company plc stock logo
PRGO
Perrigo
0.94
2.56
1.77
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
3.49
3.34

Institutional Ownership

CompanyInstitutional Ownership
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Harrow, Inc. stock logo
HROW
Harrow
72.76%
Perrigo Company plc stock logo
PRGO
Perrigo
95.91%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.70%
Harrow, Inc. stock logo
HROW
Harrow
15.16%
Perrigo Company plc stock logo
PRGO
Perrigo
0.70%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
5.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
250119.43 million114.00 millionOptionable
Harrow, Inc. stock logo
HROW
Harrow
18236.69 million30.75 millionOptionable
Perrigo Company plc stock logo
PRGO
Perrigo
8,900136.46 million135.47 millionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
14063.62 million58.02 millionOptionable

Recent News About These Companies

HC Wainwright Brokers Decrease Earnings Estimates for RYTM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$32.13 +0.44 (+1.39%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$31.70 -0.43 (-1.34%)
As of 04:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Harrow stock logo

Harrow NASDAQ:HROW

$26.66 +2.26 (+9.26%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$26.89 +0.23 (+0.86%)
As of 04:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Perrigo stock logo

Perrigo NYSE:PRGO

$26.99 -0.02 (-0.07%)
Closing price 05/12/2025 03:59 PM Eastern
Extended Trading
$26.65 -0.34 (-1.26%)
As of 04:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$58.97 +1.59 (+2.77%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$59.20 +0.23 (+0.39%)
As of 04:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.